VGG1110E1079 - Common Stock
BHV-1300 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD. Subcutaneous BHV-1300 achieved rapid...
Reported expanded safety results from BHV-7000 Phase 1 multiple ascending dose studies, including the once-daily extended-release formulation being evaluated...
In the RESILIENT SMA study, taldefgrobep alpha showed clinically meaningful improvements in motor function at all timepoints on the Motor Function...
Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million Achieved positive topline trial...
The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease.
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class, potent, orally...
The company is hoping to soon file for approval of what could be the first SCA treatment.
Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale...
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE...